Fidelity Investments’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Fidelity Investments’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-75,636	Closed	-$2.55M	–	4297
2019 Q1	$2.55M	Sell	75,636 -900	-1%	-$30.1K	﹤0.01%	2240
2018 Q4	$2.23M	Sell	76,536 -42,222	-36%	-$1.87M	﹤0.01%	2252
2018 Q3	$7.32M	Sell	118,758 -66,398	-36%	-$4.49M	﹤0.01%	2026
2018 Q2	$13.7M	Sell	185,156 -14,311	-7%	-$1.12M	﹤0.01%	1845
2018 Q1	$13.1M	Sell	199,467 -63,487	-24%	-$4.79M	﹤0.01%	1872
2017 Q4	$22.1M	Sell	262,954 -10,180	-4%	-$998K	﹤0.01%	1677
2017 Q3	$31.5M	Sell	273,134 -5,880	-2%	-$619K	﹤0.01%	1523
2017 Q2	$32.6M	Sell	279,014 -6,854	-2%	-$851K	﹤0.01%	1484
2017 Q1	$35.3M	Sell	285,868 -57,628	-17%	-$7.55M	﹤0.01%	1470
2016 Q4	$46.8M	Sell	343,496 -965	-0.3%	-$171K	0.01%	1332
2016 Q3	$68.5M	Buy	344,461 +105,107	+44%	+$18.1M	0.01%	1163
2016 Q2	$31M	Buy	239,354 +115,854	+94%	+$12.9M	﹤0.01%	1478
2016 Q1	$11.5M	Sell	123,500 -66,145	-35%	-$7.2M	﹤0.01%	1896
2015 Q4	$38.4M	Buy	189,645 +89,645	+90%	+$16M	0.01%	1363
2015 Q3	$14.5M	Hold	100,000	–	–	﹤0.01%	1787
2015 Q2	$21.3M	Buy	+100,000	New	+$24.5M	﹤0.01%	1704

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments's BLCM Position: Q2 2019 in Review

Fidelity Investments sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 75,636 shares — an estimated $2.55M sold.

Fidelity Investments first reported a position in BLCM in Q2 2015 and held it in 16 quarters. The position peaked at $68.5M in Q3 2016. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Fidelity Investments reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Fidelity Investments sold 75,636 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2.55M.
Fidelity Investments first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 16 quarters.
Fidelity Investments's Bellicum Pharmaceuticals, Inc. position peaked at $68.5M in Q3 2016.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Fidelity Investments's 13F filing for Q2 2019, filed 13 Aug 2019.